DIA and the Food and Drug Administration (FDA) Office of Women’s Health (OWH), in collaboration with the Center for Information and Study on Clinical Research Participation (CISCRP) and Society for Women’s Health Research (SWHR), will host Partnerships to Advance Patient Recruitment and Retention in Clinical Research from October 14-15, in Rockville, MD.
This first FDA co-sponsored patient recruitment and retention conference will explore:
- Recruitment and retention barriers and motivations for different subgroup populations in clinical trials
- Regulatory and public health impact of the under-representation of women, elderly, and minority groups in clinical trials
- Current best practices to ensure adequate recruitment and retention of patients in clinical trials
- Innovative and successful solutions/strategies for recruiting and retaining diverse populations in clinical trials
Dr. Margaret A. Hamburg, MD, FDA Commissioner, will deliver a special video welcome address.
Additional expert speakers will include:
- Phyllis Greenberger, MSW, President and CEO, SWHR
- C. Noel Bairey Merz, MD, Cedars-Sinai Medical, Preventive and Rehabilitative Cardiac Center and, Women’s Health Program
- Sheila L. Thorne, Multicultural Healthcare, Marketing Group; Stony Brook University School of Social Welfare
- Kathleen B. Drennan, TrialAdvance, The Face of Clinical Trials
- Richard A. Williams, MD, FACC, UCLA School of Medicine; The Minority Health Institute, Inc.; The Association of Black Cardiologists, Inc.
- Joshua M. Sharfstein, MD (Keynote speaker), Principal Deputy Commissioner, FDA
- Vivian W. Pinn, MD (Keynote speaker), Office of the Director, National Institutes of Health (NIH), DHHS
“Recruiting adequate numbers of clinical trial participants representing demographic subgroups has improved, yet developing strategies for successfully recruiting and retaining these populations remains a challenge, says Kathleen B. Drennan, President and CEO, TrialAdvance, The Face of Clinical Trials. “This conference will allow key stakeholders including pharmaceutical companies, CROs, principal investigators, physicians, government, research institutions, and IRBs to engage in shared discussions and establish action plans eliminating disparities and advancing representation of subpopulations in clinical drug trials.”
ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.